Date:5/31/2011

y statements in this press release about MultiCell Technologies' expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding the predicted size of the interventional cardiology and intravascular stent market and statements regarding the efficacy and safety of the Ideal™ BioStent.  MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2009, and all our quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to upd
'/>"/>

SOURCE MultiCell Technologies, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
2. MultiCell Technologies Launches New Web Site
3. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
4. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
5. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
6. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
7. TriLink BioTechnologies, Inc. Awarded European Patent for CleanAmp™ Primers
8. Vicor Technologies CEO David H. Fater to Present Live, Online at RetailInvestorConferences.com
9. Mind Technologies Inc. Developing Revolutionary EEG Brain Computer Interface
10. Patient Safety Technologies Reports First Quarter 2011 Results
11. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU